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Abstract
Aims: We will examine the latest advances in genomic and proteomic laboratory technology.
Through an extensive literature review we aim to critically appraise those studies which have
utilized these latest technologies and ascertain their potential to identify clinically useful
biomarkers.
Methods: An extensive review of the literature was carried out in both online medical journals
and through the Royal College of Surgeons in Ireland library.
Results: Laboratory technology has advanced in the fields of genomics and oncoproteomics. Gene
expression profiling with DNA microarray technology has allowed us to begin genetic profiling of
colorectal cancer tissue. The response to chemotherapy can differ amongst individual tumors. For
the first time researchers have begun to isolate and identify the genes responsible. New laboratory
techniques allow us to isolate proteins preferentially expressed in colorectal cancer tissue. This
could potentially lead to identification of a clinically useful protein biomarker in colorectal cancer
screening and treatment.
Conclusion: If a set of discriminating genes could be used for characterization and prediction of
chemotherapeutic response, an individualized tailored therapeutic regime could become the
standard of care for those undergoing systemic treatment for colorectal cancer. New laboratory
techniques of protein identification may eventually allow identification of a clinically useful
biomarker that could be used for screening and treatment. At present however, both expression
of different gene signatures and isolation of various protein peaks has been limited by study size.
Independent multi-centre correlation of results with larger sample sizes is needed to allow
translation into clinical practice.
Background
Colorectal cancer (CRC) is the most abundant type of
neoplasia in developed countries, and the second cause of
death among cancers [1]. Understanding the molecular
basis of the biochemical pathways involved in carcino-
genesis can facilitate diagnosis and treatment of cancer.
Current knowledge of cellular regulation indicates that
many networks operate at the epigenetic, transcriptional
and translational levels. Genomic and proteomic technol-
ogies will help further understand the intracellular signal-
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ing and gene transcription systems as well as the protein
pathways that connect extracellular microenvironment to
the serum or plasma macroenvironment [2].
Initial genomic studies focused on changes in global
expression levels, using microarray or serial analysis of
gene expression analysis [3]. Gene expression is the proc-
ess in which the inheritable information in a gene, such as
the DNA sequence, is made into a functional gene prod-
uct, such as protein or RNA. DNA microarrays allow us to
visualize the expression of potentially all genes within a
cell population or tissue sample. The analysis of this type
of data is commonly called gene expression profiling.
New advances in genomic techniques such as DNA micro-
array analysis may make possible the identification of
patients who will respond to adjuvant therapy. This could
individualise treatment regimes and avoid unnecessary
treatments in those deemed non-responders.
Genomics is also being used to search for a novel CRC
biomarker. Because CRC develops slowly via a progressive
accumulation of genetic mutations, recurrence rates and
overall mortality due to CRC is closely related to the stage
of disease at time of diagnosis [4]. Evidence exists to sug-
gest endoscopic screening by sigmoidoscopy reduces inci-
dence of distal CRC [5] and subsequent death. However,
despite the different available screening methods and
their proven benefits, morbidity and mortality associated
with CRC remains high, partly due to a low compliance
with screening [6]. If a novel biomarker that could be used
to detect CRC early were to be developed, this would have
far reaching benefits both for the individual and for health
services as a whole. Microarray analysis of colonocytes,
which are shed into the faecal stream, can be used to
detect genetic markers for CRC in faeces. Genomic exam-
ination of DNA methylation has also highlighted genes
that could potentially serve as molecular biomarkers.
Genomic advances aside, recent literature published in
the field of oncoproteomics also highlights potential
novel biomarkers to aid in the early detection of colorectal
cancer. Alterations in protein abundance, structure or
function can act as indicators of carcinogenesis prior to
development of clinical symptoms [7]. Currently carci-
noembryonic antigen (CEA) is the best characterised sero-
logical marker for CRC. However European guidelines
limit its use to the detection of recurrence for patients with
stage II or III who may be candidates for either liver resec-
tion or systemic therapy should recurrence develop [8].
Advances in protemic techniques and analytical tech-
niques in mass spectrometry provide greater opportunity
to isolate individual peptides that could be used to detect
CRC at an early stage.
Genomics
Genomics and response to chemotherapy
Radical resection is the main treatment for adenocarci-
noma of the colon. However, 50% of patients with diag-
nosed colorectal carcinoma develop liver metastasis at
some point during their lifetime [9]. The response to
chemotherapy differs amongst individual tumours
[10,11]. If a set of discriminating genes could be used for
characterisation and prediction of response, an individu-
alised tailored therapeutic regime could become the
standard of care for those undergoing systemic treatment
for CRC. Numerous molecular markers have been studied
in those undergoing adjuvant therapies. Epidermal
growth factor receptor (EGRF) expression after chemo-
therapy has been associated with disease free survival, and
expression of p21 along with MIB-1 after neoadjuvant
chemoradiotherapy predicts a worse outcome [12].
Advances in gene expression are producing studies which
claim increased efficiency in predicting response to 5-Flu-
ourouracil(5-FU)-induced apoptosis [13]. In 1991 prefer-
ential use of the orotate phosphoribosyl transferase
(OPRT) metabolic pathway in the metabolism of 5-FU
was shown to correlate with higher chemosensitivity in
CRC tissue [14]. Gene expression profiling had again
highlighted it's potential as a predictor of response to 5-
FU [15]. A recent study investigated the prognostic value
of the expression of the 5-FU metabolic enzyme genes,
including OPRT in 103 CRC patients (Duke's stage B and
C) treated with oral 5-FU-based adjuvant chemotherapy
[16]. It found that the disease-free and overall survival of
the OPRT mRNA high-expression group were significantly
longer than that of the OPRT mRNA low-expression
group.
For CRC patients being treated with leucovorin, fluorour-
acil and irinotecan (FOLFIRI), small in vivo studies have
isolated a set of 14 predictor genes of response with 100%
specificity and 92% sensitivity [17]. Here 40 patients with
synchronous and unresectable liver metastases underwent
primary tumour resection and adjuvant chemotherapy.
The 14 genes over expressed in responder tumours were
functionally classed as RNA splicing genes, regulation of
transcription, cell adhesion, cell differentiation, ion trans-
port, signal transduction, development, visual perception,
and a Golgi membrane protein gene. These genes were all
over expressed in the responder group to FOLFIRI. How-
ever these results are based on a small sample size. Further
studies of these 14 genes are necessary in a larger inde-
pendent cohort of patients. This study was the first predic-
tor classifier based on microarray gene expression in CRC.
Since it's publication there have been several further stud-
ies [18-20], but many of these have yet to show consist-
ency with regard to the gene signature being studied.World Journal of Surgical Oncology 2009, 7:36 http://www.wjso.com/content/7/1/36
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UDP glucoronosyltransferase 1 (UGT1A1) is a gene which
encodes an enzyme of the glucuronidation pathway. It's
variations have been examined in metastatic CRC patients
treated with irinotecan. A recent evidence-based review
described the proposed clinical utility of UGT1A1 geno-
typing, as three recent studies they reviewed found statis-
tically significant higher tumour response rates among
individuals homozygous for a particular allele [21]. They
concluded that a prospective RCT was necessary to exam-
ine the effects of irinotecan dose modification in CRC
patients based on their UGT1A1 genotype. This could
improve tumour response in CRC cancer patients with
various UGT1A1 genotypes, as well as minimising unnec-
essary adverse reactions such as severe neutropaenia.
The first report using DNA microarray for predicting
response to radiotherapy was published in 2006 [22]. Jap-
anese researchers identified a novel set of 33 discriminat-
ing genes that could predict responders and non-
responders to preoperative radiotherapy in rectal cancer.
Because the number of patients – especially responders –
was limited, larger prospective trials will be needed to
confirm results.
The role of a PTMA (prothymosin alpha), a gene consid-
ered to have a nuclear function related to cell proliferation
was investigated recently [23]. In this study, PTMA was
found to be upregulated in radiotherapy resistant CRC.
The researchers analysed clinical samples from 30 irradi-
ated rectal cancer patients. The expression of PTMA was
found to be statistically significantly higher in radioresist-
ant patients. PTMA expression was only significantly
upregulated in irradiated tissue. Further studies investigat-
ing it's expression in CRC tissue prior to radiotherapy are
needed in order to ascertain it's effectiveness as a predictor
of response. Only prediction of non-responders without
their having to undergo any unnecessary radiation would
be clinically useful.
A team of Korean researchers investigated whether micro-
array gene expression analysis could predict complete
response to preoperative chemoradiotherapy in rectal
cancer [24]. In their study, 46 patients (31 for training and
15 for validation testing) with rectal carcinoma under-
went preoperative RCT and surgical excision 6 weeks later.
Baseline tissue samples were collected prior to treatment.
After excision, the tumour samples were classified as com-
plete or partial responders to RCT using Dworak's tumour
regression grade system [25]. Using microarray analysis
261 genes were identified as differing between the two
groups, with the 95 top ranked of these predictor genes
being able to distinguish between partial and complete
responders in 84% of 31 training samples and 87% of the
validation samples.
Another study looking to use genomics to predict
response of CRC patients to chemoradiotherapy was pub-
lished recently [26]. The study constructed gene expres-
sion profiles of 43 biopsy specimens of locally advanced
rectal carcinomas to identify 42 genes that could differen-
tiate responders from non-responders. These genes were
mostly encoding proteins that played a role in the
nucleus, such as the transcription factor ETS2, or were
associated with transport function, such as the solute car-
rier SLC35E1 or the regulation of apoptosis, such as cas-
pase-1.
Establishing validated molecular analysis and subsequent
tumour gene-signature identification allows patients with
early stage cancer with low recurrence risk to be spared the
toxicity of systemic chemotherapy and/or radiotherapy. In
addition patients identified as non-responders would be
spared unnecessary side effects. From an economic per-
spective this would have huge benefits. However the
transfer from laboratory to bedside is proving more labo-
rious than expected. More independent laboratories need
to examine the same gene signatures. At present there is a
lack of consistency with different studies all producing
results but using different sets of genes, and often with
small numbers.
Potential genetic biomarkers
Identification of genes characteristic CRC development
could uncover biomarkers which would aid in CRC diag-
nosis and screening. Faecal-occult-blood testing (FOBT) is
currently the most widely used screening modality for
CRC. However it has poor sensitivity for detection of CRC,
with large randomised clinical trials showing only a 30%
reduction in mortality [27]. Colonocytes, which are shed
continuously and with greater frequency from CRC tissue
than normal colonic mucosa have been analysed for
genetic mutations. Several genes have thus been isolated
as potential markers for CRC. p53 and adenomatous poly-
posis coli (APC) both genetically encode tumour suppres-
sor proteins which regulate apoptosis and angiogenesis.
Although up to 60% of CRCs demonstrate p53 mutations
[28], these appear late in the genesis of CRC and so have
limited use in it's early detection. In contrast, APC appears
to be an early genetic event in the development of CRC.
However the mutations are distributed throughout the
coding region of DNA making it difficult to detect all
mutations in screening for CRC [4].
Cancer specific or "type C" DNA methylation has been
shown to lead to transcriptional silencing of various genes
such as tumour suppressor genes and genes involved in
DNA repair and apoptosis. When a large number of CRCs
were examined, some were found to accumulate high fre-
quencies of type C methylation of multiple genes. This
subset of CRC tumours is classified as having CpG islandWorld Journal of Surgical Oncology 2009, 7:36 http://www.wjso.com/content/7/1/36
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methylator phenotype. Using DNA microanalysis identifi-
cation of a number of genes that are epigenetically
silenced in colorectal cancer has been made possible.
One in-vitro using tissue from 124 tumours highlighted
the SFRP gene [29]. It reported that hypermethylation of
the four genes in this family occurs with high frequency in
CRC, potentially providing for construction of molecular
marker panel for CRC detection. A further in-vitro study
described high incidence of BRAF mutations and micro-
satellite instability (MSI) in a group of tumours with high
methylation frequency [30].
Most recently, oncostatin M (OSM), a member of the
interleukin-6 cytokine family has been examined. This
gene family inhibits cell proliferation and induces apop-
tosis in cancers. The OSM-receptor in CRC was studied in
a recent publication [31]. In this study of 98 CRCs, silenc-
ing of the OSM-receptor by methylation was observed in
90% of cases.
Studies involving DNA methylation have highlighted sev-
eral genes which play an important part in CRC carcino-
genesis. Their potential for development into molecular
markers for early CRC diagnosis is evident. However
despite these findings, conflicting reports exist associating
type C methylation with normal aging, or with microsat-
ellite instability rather than carcinomatous change [32].
Recent advances in genomic technology such as ultra-
high-throughput microarray analysis allow us describe
previously inaccessible components of the genome.
Although it has been used to identify tumour suppressor
genes in patients with multiple myeloma, it has yet to be
applied to colorectal cancer [33].
The pathway to develop a clinically useful biomarker from
a potential gene identified is a long one, and further cor-
relative studies are needed to cement and develop the
genetic associations highlighted in these recent publica-
tions.
Other potential biomarkers can be may be isolated
through advances in proteomics. Protein biomarkers are
based on aberrant protein signalling circuits represented
by post-translational modifications. As such proteomics
could be expected to render better insight than genomics
with regard to developing a biomarker for screening for
disease screening, progression and treatment response
[34].
Oncoproteomics
2-DE
To date the primary technique for proteomic biomarker
discovery has been Two Dimensional Electrophoresis (2-
DE). Using this method subcellular fractions are separated
by charge and then by molecular weight. These proteins
are mixed on a gel then scanned to generate a map for
each labelled protein. Maps from different patient sam-
ples can then be compared to ascertain which proteins are
expressed in one sample and not another [35]. However,
the comparison between two different gel samples
remains difficult. Each gel runs slightly differently, which
makes gel-to-gel comparison laborious. Recently, 2D dif-
ference-in-gel electrophoresis (DIGE) has been intro-
duced. This technique minimises gel-to-gel variations
[36]. However the exchange of 2-DIGE data between lab-
oratories has been a problem due to spatial irreproduci-
bility between 2D gels generated [37].
Standing alone 2-DE is purely a descriptive technique and
as such must be coupled with analytical methods such as
Mass Spectrometry (MS). Proteins are extracted from the
2-DE gel and characterised for protein identification using
structural information such as peptide mass or amino acid
sequence. These values are checked against a known data-
base and the proteins thus identified.
2-DE was first used to study protein profiles in carcinoma
cells by the Gottesman's group as early as 1986 [38]. Sev-
eral publications have investigated the utility of 2-DE in
CRC, with the idea of identifying a clinical biomarker
using proteomics in it's infancy [39-43], and recent stud-
ies have identified potential biomarkers which might be
used to screen for CRC.
One such study demonstrated the down-regulation of
secretagogin, a protein expressed in neuroendocrine cells
of the colonic crypts in carcinomatous mucosal cells
involved in calcium-binding. The study concluded that
expression of secretagogin in non-neuronal and non-neu-
roendocrine cells may represent aberrant expression of the
protein and may be related to de- or trans-differentiation
phenomena. This was an invitro study using immunohis-
tochemistry, and so further in vivo studies are needed for
it to progress to a clinical setting [44]. However, it has cer-
tainly been highlighted as a potential for the future. Not
alone implicated in CRC, secretagogin expression is cur-
rently under scrutiny in several tumour types, with recent
studies examining it's role in prostatic adenocarcinoma,
pituitary adenomas, carcinoid tumours and their metas-
tases as well as neuroendocrine tumours from the lung,
pancreas and adrenal gland [45-47]. In a study published
by the department of Neurosurgery in Vienna, expression
of secretagogin in endothelial cells of blood vessels in
some meningiomas, haemangiopericytomas and hae-
mangioblastomas led to the theory that it is implicated in
angiogenic activity in human cancer [48].
Further 2-DE studies include a piece from Singapore in
2006 which examined 7 pairs of samples (one of the pair
from CRC tissue, the other from adjacent normal tissue)World Journal of Surgical Oncology 2009, 7:36 http://www.wjso.com/content/7/1/36
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from 7 patients with diagnosed stage 3 CRC [49]. In this
study, DIGE was used to compare between gel samples.
Here, glycolytic enzyme proteins were demonstrated to be
up regulated in the tumour samples. Mirroring this, phos-
phoenolpyruvate carboxylase, a key regulatory enzyme in
gluoneogenesis was found to be down regulated. Also
down regulated were enzymes at the early entrance of the
tricarboxylic acid cycle, suggesting it's impairment in
tumour cells. These extensive alterations in metabolic
pathways have potential for design of novel biomarkers.
Unwin et al [50] were the first to demonstrate by pro-
teomics that the glycolytic pathway was elevated in renal
cancer tissue (named "The Warburg effect"). A subsequent
study supported this observation in 24 classes of cancer
tissue [51]. But it remains controversial whether the
increase of glycolytic activity is due to inherent metabolic
alterations at all. It may simply be secondary to the anaer-
obic environment of tumour tissue [52].
MALDI-TOF
In addition to 2-DE, promising new methods are now
being used in the search for a new biomarker. Using
Matrix-Assisted Laser Desorption/Ionization – Time of
Flight technique (MALDI-TOF) the sample to be analysed
is mixed with an energy absorbing matrix molecule which
absorbs light at a predetermined wavelength. The sample
is irradiated with a laser to convert the crystalline matrix
to a gas, and peptide ions are ejected from the target sur-
face. They can then be directed down a vacuum chamber
and separated based on their time of flight. These different
times of flights for different proteins are then used to gen-
erate a 3 dimensional algorhythm, which can have several
thousand data points, with particular protein ion clusters
being evident as graph peaks.
As well as a small recent in-vivo study identifying proteins
overly expressed in CRC cells as compared to normal
colonic mucosa [53], MALDI-TOF has now been used to
differentiate CRC patients from healthy controls [54]. In a
randomised block design, pre-operative serum samples
obtained from 66 colorectal cancer patients and 50 con-
trols were used to generate high-resolution MALDI-TOF
protein profiles. Thirty-four patients out of thirty-seven
with early stage disease (stage 1 and 2) and all patients
with stage 3 or 4 disease were correctly classified as having
cancer. As a confounder however, there was significant
difference in age between groups, with the control group
being younger than the CRC patients. Also, because of
small sample size, a further independent validation study
would be necessary to add weight to these findings.
MALDI-TOF technology is also being applied in the search
to predict metastasis in known cases of CRC. Two CRC cell
lines with different metastatic potentials, SW480 and
SW620, were recently investigated using MALDI-TOF to
search for potential markers for predicting CRC metasta-
sis. Heat Shock Protein (Hsp) 27 overexpression was
found to relate to metastatic behaviour in a CRC cell [55].
Hsp27 is a cytoprotective chaperone that is phosphoacti-
vated during cell stress that prevents aggregation and/or
regulates activity and degradation of certain client pro-
teins. For more than 10 years, HSP 27 has been under the
spotlight for it's role in carcinogenesis [56-59] and it has
also recently been implicated in irinotecan resistance in
CRC [60]. However in these cell lines such results are only
stepping stones in the formation of larger in-vitro studies
necessary.
A further MALDI-TOF study targeted T Lymphoma inva-
sion and metastasis 1 (Tiam 1), a guanine nucleotide
exchange factor that activates Rac (a GTPase responsible
for stimulating cell spreading and migration). Having
found that Tiam1 was highly related to the metastatic
potential of CRC [61], the team then used the MALDI-
TOF technology to identify 11 differentially expressed
proteins were identified in the CRC HT29 cell line trans-
fected with Tiam [62]. The identification of these down-
stream targets of Tiam1 (one of which included Hsp 27)
may eventually allow clinicians to identify CRC patients
at high risk of metastasis.
SELDI-TOF
Surface enhanced laser desorption ionization/time of
flight (SELDI-TOF) is a new method of complex protein
lysis based on MALDI technology. Using SELDI, the pro-
teins from a given sample are selectively retained on a
platform using chemical or biological agent. This selective
retention based upon intrinsic peptide properties allows
for the isolation and subsequent analysis of less abundant
proteins. As in MALDI-TOF, ionisation again occurs using
laser emission, and the peptide ions thus formed then
guided into the MS analyser.
The first SELDI-TOF study attempted to differentiate CRC
patients from those with colorectal adenoma. Seven pro-
tein peaks were isolated as potential biomarkers, but
unfortunately these were not specific to CRC [63].
Another study comprised of two sets of samples [64]. The
first samples were from 40 CRC patients (all Dukes' D)
and 49 controls. The second set consisted of samples from
37 CRC patients and 31 healthy controls. They reported
three potential biomarkers with a sensitivity and specifi-
city between 65% and 90%. A further study lent weight to
the theory that SELDI-TOF could be used to distinguish
CRC patients from healthy controls [65]. The major fail-
ing in these studies is their investigation of unrelated pro-
teins. Multiple studies of the same protein peaks
producing similar results are needed before transition to
clinical practice can occur.World Journal of Surgical Oncology 2009, 7:36 http://www.wjso.com/content/7/1/36
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SELDI-TOF is not without it's limitations. As with any
other analytical technique, not all proteins can be visual-
ised well. Sensitivity for higher molecular weight proteins
is lower than for those in the less than 20 kDa range. Also
creating a reliable protein profile from biological samples
remains a problem, as in many cases mass resolution is
found to be too low. This makes data comparison and ver-
ification between laboratories difficult [66].
SELDI-TOF technology is has recently been applied to the
identification of responders and non-responders to neo
adjuvant chemoradiotherapy (RCT). A study by Smith
F.M. et al [67] used SELDI-TOF MS to identify 14 protein
peaks from serum samples taken 24–48 hours post com-
mencement of RCT in 20 patients with rectal cancer.
While there was no significant difference in baseline pro-
tein peaks, protein peaks at 24 hours post beginning RCT
were significant. As such this study claims that these iso-
lated protein peaks may potentially be used to determine
responders from non-responders to RCT, but not without
their undergoing RCT initially.
Granted avoiding unnecessary RCT complications in non-
responders would be a noteworthy achievement, but even
more noteworthy would be the sensitisation of these drug
resistant patients to their chemo-therapeutic agent. In a
recent review Zhang J-T et al mention several mechanisms
of resistance only recently discovered using proteomic
technology [68]. Notable different proteins associated
with chemotherapy drug resistance in CRC highlighted in
this review included Hsp27 (described previously),
Anexin IV (like secretagogin, another calcium-binding
protein) as well as 14-3-3sigma (a protein involved in reg-
ulation of the cell cycle). The Anexin family of proteins
have been investigated before for their role in carcinogen-
esis. There have already been studies of their expression in
renal clear cell [69] and prostate carcinoma [70]. 14-3-
3sigma has previously been investigated for it's role not
only in CRC [71] but also in breast cancer and pancreatic
adenocarcinoma [72,73].
Unfortunately it would be overly optimistic to hope that
targeting these isolated proteins would increase patient
sensitivity in non-responders since resistance of a given
tumour to chemotherapeutic agents likely has multiple
mechanisms of resistance [68]. Combination therapies
targeting multiple proteins to sensitise the drug resistant
patient is a goal to strive for in the future of cancer treat-
ment, but technology has not advanced sufficiently to
allow that yet.
Advances in mass spectrometry
Mass spectrometry (MS) has become the analytical tool of
choice in proteomic study owing to it's quantitative capa-
bility and facility to interface with the different chromato-
graphic separation methods.
The conventional pipeline for biomarker development
involves a discovery phase, through advances in pro-
teomic technology described above combined with MS
followed by validation and clinical application, usually
on an alternative platform, such as immunoassay. Though
the most sensitive, the development of an immunoassay
is time consuming when antibodies are not available and
need to be conceived. Mass spectrometry analysis driven
in quantitative multiple reaction monitoring (MRM)
mode is now appearing as a promising alternative to
quantify proteins in biological fluids. This mode conducts
both biomarker discovery and validation on the same
platform, thus obviating the need for parallel assay devel-
opment [74]. This is both time saving and cost effective.
In MRM, MS analysis time is focused only on analytes of
specific masses, while all others are excluded. Fragment-
ing the analyte and monitoring both parent and one or
more product ions simultaneously can also attain further
specificity. The application of MRM to proteomic analysis
has only recently been adopted because of advances in MS
instrumentation. To date there are very few publications
describing the use of MRM for detection of plasma
biomarkers. These studies highlighted fibulin-2 as a breast
cancer marker in mice [75], and CEA as a lung cancer
marker [76]. It's application to CRC has yet to produce a
definite potential biomarker.
Fourier transform ion cyclotron resonance (FT-ICR)
instruments are currently used in proteome analysis to
analyse proteins and peptides with high resolution and
mass accuracy. In FT-ICR, ions from multiple laser shots
are accumulated in a hexapole and then guided with a
quadrupole ion field into the ICR cell where the ions
cyclotron in a magnetic field. Ion frequencies are then
measured, and these frequencies resolved into sinusoidal
curves using fourier analysis. Unfortunately the high costs
and complexity of these instruments limits their use [77].
A more compact less costly mass spectrometer has been
developed in the Linear trap quadrupole (LTQ) Orbitrap.
The LTQ Orbitrap consists of a spindle-like central elec-
trode and a barrel-like outer electrode. When voltage is
applied between the two, ions injected into the Orbitrap
they experience a monotonic increase in electric field
strength which contracts the radius of the ion cloud, thus
decreasing the possibility of losing ions to collusions with
the outer electrode [78]. This new analytical tool has high
resolving power with good mass accuracy to reduce false
positive peptide identifications. It has yet to be used to
develop a CRC biomarker but such technological
advances hold promise for protein identification with
high specificity.World Journal of Surgical Oncology 2009, 7:36 http://www.wjso.com/content/7/1/36
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Absolute quantification (AQUA) is a method many labo-
ratories use for MS-based biomarker validation [79]. In an
AQUA study, a peptide containing a stable-isotope
labeled amino acid is developed based on the sequence of
a peptide that is being targeted for quantitation. This syn-
thesized peptide is spiked into the complex proteome
sample and used as an internal standard for quantitation
purposes. Use of AQUA for validation of biomarkers
tends to be less time consuming than MS-based quantita-
tion of peptides. However each synthesized peptide needs
to be manufactured individually, which makes concurrent
quantitation of multiple peptides difficult.
Using the various technologies described here, MS-based
discovery studies have identified a huge number of poten-
tial biomarkers for specific diseases. Presently, the focus is
on developing MS-based MRM scanning methods to
measure the absolute quantity of known proteins within
complex clinical samples [78]. To further the discovery of
a clinically effective biomarker there is a need for targeted
quantitative methods of proteomic profiling and these
new advances make this increasingly possible. However
the cost of MS instruments combined with lack of highly
specific antibodies for many proteins for MS-based
biomarker validation methods still needs to be further
addressed.
Conclusion
These are all noteworthy discoveries, but are they viable
for translation into everyday clinical practice? We must
remember that the use of mass spectrometry to develop
individual protein spectra is not in itself a realistically
practical method of screening from a cost effective view-
point. Rather it is a stepping-stone towards the develop-
ment of a useful biomarker. Since screening for colorectal
cancer is cost effective [79], if a simple blood biomarker
for colorectal cancer could be developed it would have
huge financial implications for health services worldwide.
There are many obstacles to overcome in the future appli-
cation of proteomics and genomics in clinical practice. No
solitary biomarker is considered adequately sensitive and
specific for CRC screening. Rather it is expected that the
results of multiple markers will need to be combined to
yield accurate classification [80]. There remains a lack of
clear guidelines for manufacturing and laboratory practice
for all phases of biomarker development [81]. Quality
control must be implemented to assure reproducibility
and accuracy. To date there remains a lack of consistent
investigation into specific gene signatures or protein
peaks. Different studies of limited sizes have highlighted
numerous potential biomarkers. There is not enough
independent multi-centre correlation to confidently claim
that identification of a biomarker is imminent. It is at least
however possible. And with further advances in labora-
tory technology, and larger corroborative studies, it
remains a goal for the future.
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